Report on two cases of hemolytic paroxysmal nocturnal hemoglobinuria in patients with non-hypoplastic myelodysplastic syndrome, highlighting treatment with complement inhibitors.
Key Points
Two cases of paroxysmal nocturnal hemoglobinuria were identified in patients with myelodysplastic syndrome, showing effective treatment.
In both cases, patients displayed significant anemia and received treatment with complement inhibitors ravulizumab and pegcetacoplan, indicating their efficacy.
Assessment of paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndromes is crucial for appropriate diagnosis and management.
Complement inhibitors are underrepresented in studies for non-hypoplastic myelodysplastic syndrome, yet standard doses appear effective.
Cite This Study
Briggeler-Mani et al. (2025) studied this question.